TScan Therapeutics Inc. (TCRX)
NASDAQ · Healthcare
TScan Therapeutics Inc. annual/quarterly shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- TScan Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 123.1M, a 48.91% decrease year-over-year.
- TScan Therapeutics Inc. shareholder equity for 2025 were 123.1M, a 48.91% decrease from 2024.
- TScan Therapeutics Inc. shareholder equity for 2024 were 241.0M, a 59.72% increase from 2023.
- TScan Therapeutics Inc. shareholder equity for 2023 were 150.9M, a 51.73% increase from 2022.
- TScan Therapeutics Inc. shareholder equity for 2022 were 99.4M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| TScan Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $123 |
| 2024 | $241 |
| 2023 | $151 |
| 2022 | $99 |
| 2021 | $161 |
| 2020 | $-42 |
| TScan Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $123 |
| 2024-12-31 | $241 |
| 2023-12-31 | $151 |
| 2022-12-31 | $99 |
| 2021-12-31 | $161 |
| 2020-12-31 | $-42 |
TScan Therapeutics Inc. Shareholder Equity — FAQ
TScan Therapeutics Inc. (TCRX) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TCRX's shareholder equity history?
The chart and table above show TScan Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.